Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center
Introduction Palbociclib, the first CDK4/6 inhibitor, has shown promising results in phase III clinical studies by enhancing the efficacy of endocrine therapy (ET) in HR +/HER2– advanced breast cancer. However, real-world data on its use in patients with visceral metastatic disease are li...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2025-04-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1790584 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850130314223943680 |
|---|---|
| author | Sandeep K. S Sandhya Appachu Ravi B. Diwaker Sai Vivek Vijai V.S. Simha |
| author_facet | Sandeep K. S Sandhya Appachu Ravi B. Diwaker Sai Vivek Vijai V.S. Simha |
| author_sort | Sandeep K. S |
| collection | DOAJ |
| description |
Introduction Palbociclib, the first CDK4/6 inhibitor, has shown promising results in phase III clinical studies by enhancing the efficacy of endocrine therapy (ET) in HR +/HER2– advanced breast cancer. However, real-world data on its use in patients with visceral metastatic disease are limited. We aimed to assess the effectiveness and tolerability of palbociclib in this high-risk population across different lines of treatment. |
| format | Article |
| id | doaj-art-775ff33e236f47bdb32c70a14f244201 |
| institution | OA Journals |
| issn | 0971-5851 0975-2129 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-775ff33e236f47bdb32c70a14f2442012025-08-20T02:32:44ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58510975-21292025-04-01460216817310.1055/s-0044-1790584Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer CenterSandeep K. S0https://orcid.org/0000-0003-2110-1233Sandhya Appachu1Ravi B. Diwaker2Sai Vivek3Vijai V.S. Simha4Department of Medical Oncology, Sri Shankara Cancer Hospital and Research Centre, Bengaluru, Karnataka, IndiaDepartment of Medical Oncology, Sri Shankara Cancer Hospital and Research Centre, Bengaluru, Karnataka, IndiaDepartment of Medical Oncology, Sri Shankara Cancer Hospital and Research Centre, Bengaluru, Karnataka, IndiaDepartment of Medical Oncology, Sri Shankara Cancer Hospital and Research Centre, Bengaluru, Karnataka, IndiaDepartment of Medical Oncology, Sri Shankara Cancer Hospital and Research Centre, Bengaluru, Karnataka, India Introduction Palbociclib, the first CDK4/6 inhibitor, has shown promising results in phase III clinical studies by enhancing the efficacy of endocrine therapy (ET) in HR +/HER2– advanced breast cancer. However, real-world data on its use in patients with visceral metastatic disease are limited. We aimed to assess the effectiveness and tolerability of palbociclib in this high-risk population across different lines of treatment.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1790584CDK4/6 inhibitorspalbociclibvisceral metastatic breast cancermetastatic hormone-positive breast cancer |
| spellingShingle | Sandeep K. S Sandhya Appachu Ravi B. Diwaker Sai Vivek Vijai V.S. Simha Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center Indian Journal of Medical and Paediatric Oncology CDK4/6 inhibitors palbociclib visceral metastatic breast cancer metastatic hormone-positive breast cancer |
| title | Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center |
| title_full | Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center |
| title_fullStr | Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center |
| title_full_unstemmed | Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center |
| title_short | Clinical Benefit and Safety of Palbociclib in Hormone Positive Breast Cancer with Visceral Metastasis: Real-World Experience from a Tertiary Cancer Center |
| title_sort | clinical benefit and safety of palbociclib in hormone positive breast cancer with visceral metastasis real world experience from a tertiary cancer center |
| topic | CDK4/6 inhibitors palbociclib visceral metastatic breast cancer metastatic hormone-positive breast cancer |
| url | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0044-1790584 |
| work_keys_str_mv | AT sandeepks clinicalbenefitandsafetyofpalbociclibinhormonepositivebreastcancerwithvisceralmetastasisrealworldexperiencefromatertiarycancercenter AT sandhyaappachu clinicalbenefitandsafetyofpalbociclibinhormonepositivebreastcancerwithvisceralmetastasisrealworldexperiencefromatertiarycancercenter AT ravibdiwaker clinicalbenefitandsafetyofpalbociclibinhormonepositivebreastcancerwithvisceralmetastasisrealworldexperiencefromatertiarycancercenter AT saivivek clinicalbenefitandsafetyofpalbociclibinhormonepositivebreastcancerwithvisceralmetastasisrealworldexperiencefromatertiarycancercenter AT vijaivssimha clinicalbenefitandsafetyofpalbociclibinhormonepositivebreastcancerwithvisceralmetastasisrealworldexperiencefromatertiarycancercenter |